PDF(Pubmed)
Abstract：
UNASSIGNED: Although aspirin can effectively reduce the occurrence of atherothrombosis, it is significantly associated with increased bleeding, with elderly individuals being at increased risk of cardiovascular diseases (CVD) and hemorrhage. This study aims to evaluate the efficacy and safety of aspirin 50 mg/d and 100 mg/d for the prevention and management of CVD in Chinese elderly.
UNASSIGNED: The Low-dose Aspirin for Primary and Secondary Prevention of Cardiovascular Disease in the Elderly Study (LAPIS) is a multicenter, prospective, observational cohort study, this study was a single-center interim analysis of LAPIS. Patients aged ≥60 and required long-term aspirin for primary and secondary prevention of CVD were eligible. From Apr 1, 2019 to Feb 28, 2022, 165 patients who received 50 mg/d aspirin and 261 patients who received 100 mg/d aspirin were included in the study. The incidence of major cardiovascular events (MACEs), bleeding events, and gastrointestinal adverse events were compared between two groups.
UNASSIGNED: After adjusting for patient characteristics using propensity score matching, aspirin 100 mg/d was associated with increased incidence rates of total bleeding events (28.34 vs.17.25 events/100 patient-years, HR 1.671, 95% CI 1.024-2.712, P = 0.040) and minor bleeding events (27.63 vs.15.92 events/100 patient-years, HR 1.738, 95% CI 1.056-2.861, P = 0.031), whereas the incidence of MACE (6.35 vs 6.65 events/100 patient-years, HR 0.921, 95% CI 0.399-2.127, P = 0.848) and gastrointestinal adverse events (12.73 vs.10.42 events/100 patient-years, HR 1.206, 95% CI 0.623-2.337, P = 0.578) were similar between the two groups. Multivariate Cox analysis identified that aspirin dose (100 mg/d vs. 50 mg/d, HR 1.918, 95% CI 1.137-3.235, P = 0.015), concomitant use of other antiplatelets (HR 1.748, 95% CI 1.009-3.028, P = 0.046) and anticoagulants (HR 2.501, 95% CI 1.287-4.862, P = 0.007) were independently associated with bleeding events.
UNASSIGNED: 50 mg/d aspirin may be preferred to balance the safety and effectiveness in Chinese individuals over 60 years of age who need long-term aspirin for the prevention and management of CVD.
UNASSIGNED: ChiCTR1900021980 (chictr.org.cn). Registered on 19 March 2019.
UNASSIGNED: The Low-dose Aspirin for Primary and Secondary Prevention of Cardiovascular Disease in the Elderly Study (LAPIS) is a multicenter, prospective, observational cohort study, this study was a single-center interim analysis of LAPIS. Patients aged ≥60 and required long-term aspirin for primary and secondary prevention of CVD were eligible. From Apr 1, 2019 to Feb 28, 2022, 165 patients who received 50 mg/d aspirin and 261 patients who received 100 mg/d aspirin were included in the study. The incidence of major cardiovascular events (MACEs), bleeding events, and gastrointestinal adverse events were compared between two groups.
UNASSIGNED: After adjusting for patient characteristics using propensity score matching, aspirin 100 mg/d was associated with increased incidence rates of total bleeding events (28.34 vs.17.25 events/100 patient-years, HR 1.671, 95% CI 1.024-2.712, P = 0.040) and minor bleeding events (27.63 vs.15.92 events/100 patient-years, HR 1.738, 95% CI 1.056-2.861, P = 0.031), whereas the incidence of MACE (6.35 vs 6.65 events/100 patient-years, HR 0.921, 95% CI 0.399-2.127, P = 0.848) and gastrointestinal adverse events (12.73 vs.10.42 events/100 patient-years, HR 1.206, 95% CI 0.623-2.337, P = 0.578) were similar between the two groups. Multivariate Cox analysis identified that aspirin dose (100 mg/d vs. 50 mg/d, HR 1.918, 95% CI 1.137-3.235, P = 0.015), concomitant use of other antiplatelets (HR 1.748, 95% CI 1.009-3.028, P = 0.046) and anticoagulants (HR 2.501, 95% CI 1.287-4.862, P = 0.007) were independently associated with bleeding events.
UNASSIGNED: 50 mg/d aspirin may be preferred to balance the safety and effectiveness in Chinese individuals over 60 years of age who need long-term aspirin for the prevention and management of CVD.
UNASSIGNED: ChiCTR1900021980 (chictr.org.cn). Registered on 19 March 2019.
摘要：
UASSIGNED：尽管阿司匹林可以有效减少动脉粥样硬化的发生，它与出血增加显著相关，老年人患心血管疾病（CVD）和出血的风险增加。本研究旨在评价阿司匹林50mg/d和100mg/d在中国老年人心血管疾病预防和管理中的有效性和安全性。
UNASSIGNED：低剂量阿司匹林用于老年人心血管疾病一级和二级预防的研究（LAPIS）是一个多中心，prospective,观察性队列研究，本研究为LAPIS单中心中期分析.年龄≥60岁且需要长期服用阿司匹林进行CVD一级和二级预防的患者符合资格。从2019年4月1日至2022年2月28日，165名接受50mg/d阿司匹林的患者和261名接受100mg/d阿司匹林的患者被纳入研究。主要心血管事件（MACEs）的发生率，出血事件,比较两组胃肠道不良事件发生情况。
未经评估：使用倾向评分匹配调整患者特征后，阿司匹林100mg/d与总出血事件发生率增加相关(28.34vs.17.25事件/100患者年,HR1.671,95%CI1.024-2.712,P=0.040)和轻微出血事件(27.63vs.15.92事件/100患者年,HR1.738，95%CI1.056-2.861，P=0.031），而MACE的发生率（6.35vs6.65事件/100患者年，HR0.921，95%CI0.399-2.127，P=0.848）和胃肠道不良事件（12.73vs.10.42事件/100患者年，两组HR1.206，95%CI0.623-2.337，P=0.578）相似。多变量Cox分析确定阿司匹林剂量（100mg/d与50mg/d,HR1.918，95%CI1.137-3.235，P=0.015），同时使用其他抗血小板(HR1.748,95%CI1.009-3.028,P=0.046)和抗凝剂(HR2.501,95%CI1.287-4.862,P=0.007)与出血事件独立相关.
UNASSIGNED：在60岁以上需要长期服用阿司匹林预防和治疗心血管疾病的中国人群中，为了平衡安全性和有效性，可能首选50mg/d阿司匹林。
未经批准：ChiCTR1900021980(chictr.org.cn)。2019年3月19日注册。
UNASSIGNED：低剂量阿司匹林用于老年人心血管疾病一级和二级预防的研究（LAPIS）是一个多中心，prospective,观察性队列研究，本研究为LAPIS单中心中期分析.年龄≥60岁且需要长期服用阿司匹林进行CVD一级和二级预防的患者符合资格。从2019年4月1日至2022年2月28日，165名接受50mg/d阿司匹林的患者和261名接受100mg/d阿司匹林的患者被纳入研究。主要心血管事件（MACEs）的发生率，出血事件,比较两组胃肠道不良事件发生情况。
未经评估：使用倾向评分匹配调整患者特征后，阿司匹林100mg/d与总出血事件发生率增加相关(28.34vs.17.25事件/100患者年,HR1.671,95%CI1.024-2.712,P=0.040)和轻微出血事件(27.63vs.15.92事件/100患者年,HR1.738，95%CI1.056-2.861，P=0.031），而MACE的发生率（6.35vs6.65事件/100患者年，HR0.921，95%CI0.399-2.127，P=0.848）和胃肠道不良事件（12.73vs.10.42事件/100患者年，两组HR1.206，95%CI0.623-2.337，P=0.578）相似。多变量Cox分析确定阿司匹林剂量（100mg/d与50mg/d,HR1.918，95%CI1.137-3.235，P=0.015），同时使用其他抗血小板(HR1.748,95%CI1.009-3.028,P=0.046)和抗凝剂(HR2.501,95%CI1.287-4.862,P=0.007)与出血事件独立相关.
UNASSIGNED：在60岁以上需要长期服用阿司匹林预防和治疗心血管疾病的中国人群中，为了平衡安全性和有效性，可能首选50mg/d阿司匹林。
未经批准：ChiCTR1900021980(chictr.org.cn)。2019年3月19日注册。
